The growing incidence of obesity is a burden for society and may lead to metabolic deseases. Duttal AB has documented know-how of how specially designed lipid molecules affects bodyweight. Our molecules are covered with patents in the US and in EU and has shown significant weight reductions in relevant animal models of obesity. Our vision is to use these unique assets to establish an innovative SME for further development of an anti-obesity drug for treatment of obesity and become a partner to big pharmaceutical companies. Finally, we are proud to present an interesting company with a great potential, which has the ability to improve and affect one of the world’s greatest health problems of today. Taking the next step in the development process is the next milestone on the road to moving ahead to first in man clinicalstudy.
OBS! Evenemanget är endast för inbjudna.
Värd för aktiviteten
Tid och platsDatum: 2018-09-19
Tid: 11:30 - 13:00
Plats: Ahlford Advokatbyrå Uppsala, Fyristorg 6, Uppsala